Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression
- PMID: 30278319
- DOI: 10.1016/j.jpsychires.2018.09.013
Rapid and longer-term antidepressant effects of repeated-dose intravenous ketamine for patients with unipolar and bipolar depression
Abstract
Objective: Single-dose intravenous (IV) injection of ketamine has shown rapid but transient antidepressant effects. The strategy of repeated-dose ketamine infusions to maintain antidepressant effects has received little systematic study. This study was conducted to examine the efficacy and tolerability of six ketamine infusions in Chinese patients with unipolar and bipolar depression.
Methods: Ninety seven patients with unipolar (n = 77) and bipolar (n = 20) depression received repeated ketamine infusions (0.5 mg/kg over 40 min) with continuous vital sign monitoring. Depressive symptoms were measured by the Montgomery-Asberg Depression Rating Scale (MADRS). Suicidal ideation was assessed using the Scale for Suicidal Ideations (SSI)-part 1. Anxiety symptoms were evaluated with the 14-item Hamilton Anxiety Scale (HAMA). Adverse psychopathological and dissociative effects were assessed using the Brief Psychiatric Rating Scale (BPRS)-positive symptoms and Clinician Administered Dissociative States Scale (CADSS), respectively. Patients were assessed at baseline, 4 and 24 h, and 3, 4, 5, 6, 8, 9, 10, 11, 12, 13 and 26 days.
Results: After six ketamine infusions, the response and remission rates were 68.0% and 50.5%, respectively. There were significant decreases in MADRS, SSI-part 1, and HAMA scores within four hours following the first ketamine infusion, and the decreases were sustained over the subsequent infusion period. The nonresponder subgroup manifested rapid significant improvement in suicidal ideations throughout the course of treatment. After the six ketamine infusions, the response was positively associated with the response at 24 h after the first infusion (OR = 8.94), personal income ≥4000 yuan/month (OR = 3.04), and no history of psychiatric hospitalization (OR = 3.41). Only CADSS scores had a mild but marginally significant increase after the first infusion but with a significant BPRS score decrease.
Conclusion: Six ketamine infusions were safe and effective in patients with unipolar and bipolar depression. The rapid and robust antidepressant and antisuicidal effects of ketamine infusion within four hours were sustained following the subsequent infusions.
Keywords: Depression; Efficacy; Ketamine; Response; Tolerability.
Copyright © 2018. Published by Elsevier Ltd.
Similar articles
-
A comparative analysis of antidepressant and anti-suicidal effects of repeated ketamine infusions in elderly and younger adults with depression.J Affect Disord. 2023 Aug 1;334:145-151. doi: 10.1016/j.jad.2023.04.120. Epub 2023 May 7. J Affect Disord. 2023. PMID: 37160235
-
Neurocognitive effects of six ketamine infusions and the association with antidepressant response in patients with unipolar and bipolar depression.J Psychopharmacol. 2018 Oct;32(10):1118-1126. doi: 10.1177/0269881118798614. Epub 2018 Sep 27. J Psychopharmacol. 2018. PMID: 30260273 Clinical Trial.
-
Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.Psychol Med. 2016 Feb;46(3):623-35. doi: 10.1017/S0033291715002159. Epub 2015 Oct 19. Psychol Med. 2016. PMID: 26478208 Clinical Trial.
-
Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion.J Affect Disord. 2017 Jan 15;208:560-566. doi: 10.1016/j.jad.2016.10.026. Epub 2016 Oct 26. J Affect Disord. 2017. PMID: 27839782 Free PMC article. Review.
-
Oral Ketamine for Depression: A Systematic Review.J Clin Psychiatry. 2019 Apr 16;80(3):18r12475. doi: 10.4088/JCP.18r12475. J Clin Psychiatry. 2019. PMID: 30995364
Cited by
-
A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol.BMC Psychiatry. 2020 Jun 2;20(1):268. doi: 10.1186/s12888-020-02672-3. BMC Psychiatry. 2020. PMID: 32487236 Free PMC article.
-
Effects of Chronic Social Isolation Stress and Alcohol on the Reinforcing Properties of Ketamine in Male and Female Rats.eNeuro. 2025 Mar 3;12(3):ENEURO.0452-24.2025. doi: 10.1523/ENEURO.0452-24.2025. Print 2025 Mar. eNeuro. 2025. PMID: 39993843 Free PMC article.
-
Gender differences in the antianhedonic effects of repeated ketamine infusions in patients with depression.Front Psychiatry. 2022 Sep 16;13:981981. doi: 10.3389/fpsyt.2022.981981. eCollection 2022. Front Psychiatry. 2022. PMID: 36186882 Free PMC article.
-
Ketamine and the Disinhibition Hypothesis: Neurotrophic Factor-Mediated Treatment of Depression.Pharmaceuticals (Basel). 2023 May 12;16(5):742. doi: 10.3390/ph16050742. Pharmaceuticals (Basel). 2023. PMID: 37242525 Free PMC article. Review.
-
Brain-based correlates of antidepressant response to ketamine: a comprehensive systematic review of neuroimaging studies.Lancet Psychiatry. 2023 Oct;10(10):790-800. doi: 10.1016/S2215-0366(23)00183-9. Epub 2023 Aug 22. Lancet Psychiatry. 2023. PMID: 37625426 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical